<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacokinetics of orally administered immunosuppressive drugs in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacokinetics of orally administered immunosuppressive drugs in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Pharmacokinetics of orally administered immunosuppressive drugs in adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="15%"></colgroup><colgroup span="2" width="20%"></colgroup><colgroup span="2" width="15%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug (US brand name)</td> <td class="subtitle1">Oral bioavailability</td> <td class="subtitle1">Effect of food on absorption</td> <td class="subtitle1">Metabolism and clearance*</td> <td class="subtitle1">Enzyme/transporter inhibition*</td> <td class="subtitle1">Half-life in hours (range)</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Antimetabolites</td> </tr> <tr> <td class="indent1">Mycophenolate mofetil (MMF, CellCept)</td> <td>80.7% (renal transplant patients)<br/> 94% (healthy volunteers)</td> <td> <ul> <li>High-fat meal: <span class="arrow">↓</span>Cmax by 40%; AUC is unchanged</li> <li>Should be taken on an empty stomach or at a consistent time each day in relation to meals to improve GI tolerability</li> <li>Giving total daily dose in three or four equally divided doses may improve GI tolerability</li> </ul> </td> <td>Rapidly hydrolyzed to its active metabolite mycophenolic acid (MPA), which is further metabolized by UGT to the inactive metabolite mycophenolic acid glucuronide (MPAG), which is excreted primarily via urine; MPA undergoes enterohepatic recirculation, and secondary increases in MPA levels are seen 6 to 12 hours after a dose of MMF</td> <td>None known</td> <td> <p>17.9 (11.4 to 24.4)<sup>¶</sup> (MPA)</p> MPAG can accumulate in renal failure</td> </tr> <tr> <td class="indent1">Mycophenolate sodium, enteric coated (Myfortic)<sup>Δ</sup></td> <td>72% (renal transplant patients)</td> <td> <ul> <li>High-fat meal: <span class="arrow">↓</span>Cmax by 33%; AUC is unchanged</li> <li>Should be taken on an empty stomach</li> </ul> </td> <td>Rapidly hydrolyzed to the active metabolite mycophenolic acid (MPA), which is further metabolized by UGT to the inactive metabolite mycophenolic acid glucuronide (MPAG), which is excreted primarily via urine; MPA undergoes enterohepatic recirculation, and secondary increases in MPA levels are seen 6 to 8 hours after a dose of mycophenolate sodium</td> <td>None known</td> <td> <p>12 (8 to 16) (MPA)</p> MPAG can accumulate in renal failure</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Calcineurin inhibitors</td> </tr> <tr> <td class="indent1">Cyclosporine non-modified (Sandimmune)</td> <td>Generally poor and unpredictable: <ul class="decimal_heading"> <li>10 to 89% (renal transplant patients)</li> <li>&lt;10% (liver transplant patients)</li> </ul> </td> <td> <ul> <li>High-fat meal: <span class="arrow">↑</span>(highly variable)</li> <li>Should be taken at a consistent time each day in relation to meals</li> </ul> </td> <td rowspan="2"> <p>Metabolized by CYP3A4 to reduced activity and inactive metabolites (eg, M1, M9, M4N) cleared fecally via bile</p> Substrate of P-gp</td> <td rowspan="2">Inhibitor of P-gp, BCRP, OATP1B1/1B3</td> <td> <p>19 (10 to 27)</p> Prolonged in hepatic impairment</td> </tr> <tr> <td class="indent1">Cyclosporine modified (microemulsion) (Neoral)</td> <td>23 to 50% better absorbed than non-modified formulation in renal and liver transplant patients, respectively</td> <td> <ul> <li>High-fat meal: <span class="arrow">↓</span>Cmax by 33% and <span class="arrow">↓</span>AUC by 13%</li> <li>Should be taken at a consistent time each day in relation to meals</li> </ul> </td> <td> <p>8.4 (5 to 18)</p> Prolonged in hepatic impairment</td> </tr> <tr> <td class="indent1">Tacrolimus immediate-release capsule (Prograf)</td> <td>7 to 32%</td> <td> <ul> <li>High-fat meal: <span class="arrow">↓</span>Cmax by 77% and <span class="arrow">↓</span>AUC by 37%</li> <li>High-carbohydrate meal: <span class="arrow">↓</span>Cmax by 65% and <span class="arrow">↓</span>AUC by 28%</li> <li>Should be taken on an empty stomach</li> </ul> </td> <td rowspan="3"> <p>Metabolized by CYP3A4/5 to active (eg, 13-O-demethyl) and inactive metabolites cleared fecally via bile</p> Substrate of P-gp</td> <td rowspan="3">May be an inhibitor of P-gp; supportive data are limited to in-vitro effects (ie, clinical effect is unknown)</td> <td> <p>12 (2 to 36)</p> Prolonged in severe hepatic impairment</td> </tr> <tr> <td class="indent1">Tacrolimus extended-release capsule (Astagraf XL)</td> <td>12 to 19%</td> <td> <ul> <li>High-fat meal: <span class="arrow">↓</span>Cmax by 77% and <span class="arrow">↓</span>AUC by 25%</li> <li>Should be taken preferably on an empty stomach at least 1 hour before a meal or at least 2 hours after a meal</li> </ul> </td> <td> <p>38 (35 to 41)</p> Prolonged in severe hepatic impairment</td> </tr> <tr> <td class="indent1">Tacrolimus extended-release tablet (Envarsus XR)</td> <td>50% better absorbed than immediate-release capsule</td> <td> <ul> <li>High-fat meal: <span class="arrow">↓</span>Cmax by 22% and <span class="arrow">↓</span>AUC by 55%</li> <li>Evening administration: <span class="arrow">↓</span>AUC by 15%</li> <li>Should be taken on an empty stomach</li> </ul> </td> <td> <p>31 (23 to 39)</p> Prolonged in severe hepatic impairment</td> </tr> <tr> <td class="subtitle2_left" colspan="6">mTOR inhibitors</td> </tr> <tr> <td class="indent1">Everolimus (Zortress)</td> <td>30%</td> <td> <ul> <li>High-fat meal: <span class="arrow">↓</span>Cmax by 60%; <span class="arrow">↓</span>AUC by 16%</li> <li>Should be taken at a consistent time each day in relation to meals</li> </ul> </td> <td> <p>Metabolized by CYP3A4 to six weakly active metabolites that are excreted primarily via feces</p> Substrate of P-gp</td> <td>None known</td> <td> <p>30 (19 to 41)</p> Prolonged in hepatic impairment</td> </tr> <tr> <td class="indent1">Sirolimus (Rapamune)</td> <td>18% (tablet)<br/> 14% (oral solution)</td> <td> <ul> <li>High-fat meal: <span class="arrow">↑</span>AUC by 23 to 35%</li> <li>Should be taken at a consistent time each day in relation to meals</li> </ul> </td> <td> <p>Metabolized by CYP3A4 to seven metabolites (some have weak activity) that are excreted primarily via feces</p> Substrate of P-gp</td> <td>None known</td> <td> <p>62 (46 to 78)</p> Prolonged in hepatic impairment</td> </tr> </tbody></table></div><div class="graphic_lgnd">Careful therapeutic drug monitoring (TDM) of systemic calcineurin inhibitors and mTOR inhibitors is essential due to the narrow margin between adequate immunosuppression and toxicity. Blood concentration monitoring is necessary for any change in formulation (including switch between generics or brands) and between methods of administration (eg, oral, sublingual, intravenous) to determine the need for dose alteration. Refer to accompanying text.</div><div class="graphic_footnotes"><p>MMF: mycophenolate mofetil; Cmax: maximum concentration; AUC: area under the 24-hour serum concentration × time plot; GI: gastrointestinal; MPA: mycophenolic acid (active form of mycophenolate); UGT: uridine diphosphate (UDP) glucuronosyltransferase; MPAG: mycophenolic acid glucuronide (inactive metabolite of mycophenolic acid); CYP3A4: cytochrome P450 3A4; P-gp: P-glycoprotein efflux membrane transporters (multi-drug efflux pump); mTOR inhibitors: mammalian (mechanistic) target of rapamycin inhibitors.</p>
<p>* The classification of immunosuppressive drug effects on drug metabolism are based upon US Food and Drug Administration (FDA) guidance.<sup>[1,2]</sup> Other sources may use a different classification system resulting in some agents being classified differently. Weak inhibitor effects are not listed. Clinically significant interactions can occasionally occur due to weak inhibitors, particularly if the target drug has a narrow therapeutic margin. Refer to the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program for a full review of potential interactions.</p>
<p>¶ Standard deviation 6.5 hours per US manufacturer.</p>
Δ To convert from mycophenolate mofetil (MMF, CellCept) 1000 mg every 12 hours, switch to mycophenolate sodium enteric coated (Myfortic) 720 mg every 12 hours.</div><div class="graphic_reference">References:
<ol>
<li>US Food and Drug Administration. Clinical drug interaction studies — Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry, January 2020. Available at: <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions" target="_blank">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions </a>(Accessed on June 5, 2020).</li>
<li>Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. US Food and Drug Administration. Available at: <a href="http://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers" target="_blank">www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers</a>.</li>
</ol>
<p class="extra_spacing_top">Prepared with data from Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved with additional data from US prescribing information available at <a href="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm" target="_blank">https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</a>.</p></div><div id="graphicVersion">Graphic 109680 Version 16.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
